Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sanjay J Mathew

Showing results (141-150 of 190) with videos related to

Pageof 19
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2021
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind studyAnna Feeney, Rebecca S Hock, Marlene P Freeman, et al.
Journal of Affective Disorders|August 11, 2019
Longer-term open-label study of adjunctive riluzole in treatment-resistant depressionHitoshi Sakurai, Christina Dording, Albert Yeung, et al.
Clinical Epigenetics|November 5, 2018
DNA methylation levels are associated with CRF<sub>1</sub> receptor antagonist treatment outcome in women with post-traumatic stress disorderJulius C Pape, Tania Carrillo-Roa, Barbara O Rothbaum, et al.
The Journal of Clinical Psychiatry|December 4, 2024
Difficult to Treat Depression: Focus on Approach, Algorithms, and AccessJordan F Karp, Roberta D Brinton, Jay C Fournier, et al.
JAMA Network Open|May 27, 2025
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical TrialNoam N Butterfield, Constanza Luzon Rosenblut, Maurizio Fava, et al.
Frontiers in Human Neuroscience|January 29, 2024
Prefrontal network engagement by deep brain stimulation in limbic hubsAnusha Allawala, Kelly R Bijanki, Denise Oswalt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 28, 2021
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trialMarijn Lijffijt, Nicholas Murphy, Sidra Iqbal, et al.
Biological Psychiatry|August 11, 2017
Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress DisorderBoadie W Dunlop, Elisabeth B Binder, Dan Iosifescu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 4, 2011
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew, Meena Vythilingam, James W Murrough, et al.
Journal of Affective Disorders|September 9, 2019
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depressionNaji C Salloum, Maurizio Fava, Rebecca S Hock, et al.
Pageof 19

Showing results (141-150 of 190) with videos related to

Sort By:
Pageof 19
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 5, 2021
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind studyAnna Feeney, Rebecca S Hock, Marlene P Freeman, et al.
Journal of Affective Disorders|August 11, 2019
Longer-term open-label study of adjunctive riluzole in treatment-resistant depressionHitoshi Sakurai, Christina Dording, Albert Yeung, et al.
Clinical Epigenetics|November 5, 2018
DNA methylation levels are associated with CRF<sub>1</sub> receptor antagonist treatment outcome in women with post-traumatic stress disorderJulius C Pape, Tania Carrillo-Roa, Barbara O Rothbaum, et al.
The Journal of Clinical Psychiatry|December 4, 2024
Difficult to Treat Depression: Focus on Approach, Algorithms, and AccessJordan F Karp, Roberta D Brinton, Jay C Fournier, et al.
JAMA Network Open|May 27, 2025
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical TrialNoam N Butterfield, Constanza Luzon Rosenblut, Maurizio Fava, et al.
Frontiers in Human Neuroscience|January 29, 2024
Prefrontal network engagement by deep brain stimulation in limbic hubsAnusha Allawala, Kelly R Bijanki, Denise Oswalt, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|November 28, 2021
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trialMarijn Lijffijt, Nicholas Murphy, Sidra Iqbal, et al.
Biological Psychiatry|August 11, 2017
Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress DisorderBoadie W Dunlop, Elisabeth B Binder, Dan Iosifescu, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|January 4, 2011
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trialSanjay J Mathew, Meena Vythilingam, James W Murrough, et al.
Journal of Affective Disorders|September 9, 2019
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depressionNaji C Salloum, Maurizio Fava, Rebecca S Hock, et al.
Pageof 19